Navigation Links
Omnicell Announces First Quarter 2009 Results

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its first quarter ended March 31, 2009.

GAAP results: Revenues for the first quarter of 2009 were $52.2 million, down $9.9 million or 15.9% from the fourth quarter of 2008, and down $9.9 million or 15.9% from the first quarter of 2008.

First quarter 2009 net loss as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $1.9 million, or ($0.06) per diluted share. This compares to net income of $3.3 million, or $0.10 per diluted share in the fourth quarter of 2008 and net income of $3.7 million, or $0.10 per diluted share in the first quarter of 2008.

Non-GAAP results: Excluding the impact on our results of recording $2.5 million in share-based compensation expense related to SFAS No. 123R and $2.5 million ($1.5 million net of tax) in restructuring charges related to a reduction in force, non-GAAP net income was $2.1 million for the first quarter of 2009, or $0.07 per diluted share. This compares to non-GAAP net income of $5.5 million or $0.17 per diluted share for the fourth quarter of 2008 and non-GAAP net income of $6.8 million or $0.19 per diluted share for the first quarter of 2008.

"I am pleased with our performance in Q1 2009," said Omnicell President, Chairman and CEO Randall Lipps. "Even in this challenging economy we continue to attract new customers with our focus on innovations that address medication and supply automation problems."

Omnicell Conference Call Information

Omnicell will hold a conference call today at 1:30 p.m. PDT to discuss first quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 96508596. Internet users can access the conference call at A replay of the call will be available today at approximately 2:30 p.m. PDT and will be available until 8:59 p.m. PDT on May 7. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, conference code # 96508596.

About Omnicell

Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell medication-use product lines include solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy "smart inventory" carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

Omnicell's mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company's Securities and Exchange Commission (SEC) filings and include, without limitation, the unfavorable general economic and market conditions, the tightening in the credit market, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the company to grow product backlog, retain key personnel, cut expenses, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, earnings per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, non-GAAP earnings per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operation performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of SFAS No. 123R. We recognize equity plan-related compensation expenses, which represent the fair value of all share-based payments to employees, including grants of employee stock options, as required under SFAS No. 123 (revised 2004), "Share-Based Payment" (SFAS No. 123R).

b) Restructuring charges (net of tax). We incurred charges for employee severance in connection with a reduction in force in the first quarter of 2009 which aligned our cost structure with current business expectations. These charges are not expected to be recurring and, as a non-recurring event, the financial impact is excluded from our non-GAAP results.

c) Income tax adjustments. To provide transparency into the Company's trends and performance, we consider the tax effect of one-time adjustments to current and deferred research and development tax credits which occurred in the fourth quarter of 2008, to be non-GAAP adjustments.

Management adjusts for the items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why specific items are excluded from our non-GAAP financial measures:

i) While share-based compensation calculated in accordance with SFAS No. 123R constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present our SFAS No. 123R reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, pursuant to the adoption of SFAS No. 123R, are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

  • Omnicell's stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under SFAS No.123R.
  • Other companies, including other companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.


                                Omnicell, Inc.
                Condensed Consolidated Statement of Operations
               (in thousands, except per share data, unaudited)

                                                 Three Months Ended
                                        March 31,    December 31,   March 31,
                                         2009            2008        2008
                                         ----            ----        ----
      Product revenues                 $42,295         $51,068     $52,415
      Services and other revenues        9,909          10,987       9,675
                                         -----          ------       -----
        Total revenues                  52,204          62,055      62,090

    Cost of revenues:
      Cost of product revenues          20,280          24,202      23,970
      Cost of services and other
       revenues                          6,895           6,687       5,776
      Restructuring charges              1,209               -           -
                                         -----               -           -
        Total cost of revenues          28,384          30,889      29,746

    Gross profit                        23,820          31,166      32,344
    Operating expenses:
      Research and development           3,977           4,256       4,276
      Selling, general and
       administrative                   21,499          23,152      23,207
      Restructuring charges              1,315               -           -
                                         -----               -           -
        Total operating expenses        26,791          27,408      27,483

    Income (loss) from operations       (2,971)          3,758       4,861
    Interest and other income,
     net of other expense                  182             578       1,410
                                           ---             ---       -----
    Income (loss) before
     provision for (benefit from)       (2,789)          4,336       6,271
      income taxes

    Provision for (benefit from)
     income taxes                         (918)          1,013       2,538
                                          ----           -----       -----
    Net income (loss)                  $(1,871)         $3,323      $3,733
                                       =======          ======      ======

    Net income (loss) per share-
     basic                              $(0.06)          $0.11       $0.11
                                        ======           =====       =====
    Net income (loss) per share-
     diluted                            $(0.06)          $0.10       $0.10
                                        ======           =====       =====

    Weighted average shares outstanding:
      Basic                             31,453          31,265      34,193
                                        ======          ======      ======
      Diluted                           31,453          31,849      35,582
                                        ======          ======      ======

                              Omnicell, Inc.
                   Condensed Consolidated Balance Sheets
                              (In thousands)

                                                March 31,  December 31,
                                                  2009         2008
                                                  ----         ----
                                              (unaudited)       (1)

    Current assets:
      Cash and cash equivalents                 $118,853     $120,439
      Accounts receivable, net                    60,779       57,976
      Inventories                                 10,834       12,957
      Prepaid expenses                             9,439        9,310
      Deferred tax assets                         14,871       14,871
      Other current assets                        10,636        9,434
                                                  ------        -----
        Total current assets                     225,412      224,987

    Property and equipment, net                   15,929       16,180
    Non-current net investment in sales-
     type leases                                   9,795       10,896
    Goodwill                                      24,982       24,982
    Other intangible assets                        6,142        6,706
    Non-current deferred tax assets               15,650       15,889
    Other assets                                   9,207        8,902
                                                   -----        -----
          Total assets                          $307,117     $308,542
                                                ========     ========

                   LIABILITIES AND
                    STOCKHOLDERS' EQUITY
    Current liabilities:
      Accounts payable                           $11,888       $9,377
      Accrued compensation                         7,683        8,889
      Accrued liabilities                         11,184       10,187
      Deferred service revenue                    12,291       12,084
      Deferred gross profit                       11,652       16,648
      Obligation resulting from sale of
       receivables                                   129          170
                                                     ---          ---
        Total current liabilities                 54,827       57,355

    Long-term deferred service revenue            15,593       16,782
    Other long-term liabilities                      801          848
                                                     ---          ---
        Total liabilities                         71,221       74,985

    Stockholders' equity:
        Total stockholders' equity               235,896      233,557
                                                 -------      -------

          Total liabilities and
           stockholders' equity                 $307,117     $308,542
                                                ========     ========

    (1) Information derived from our December 31, 2008 audited Consolidated
        Financial Statements.

                                  Omnicell, Inc.
                        Reconciliation of GAAP to Non-GAAP
                 (In thousands, except per share data, unaudited)

                                           Three months ended

                                                             December 31,
                                   March 31, 2009                2008
                                   --------------             ----------
                                              Earnings (loss)
                               Net income       per share-        Net
                                (loss)           diluted         income
                             ------------    ---------------  -----------
    GAAP                         $(1,871)        $(0.06)          $3,323
    Non-GAAP adjustments:
    SFAS No. 123(R)
     adjustment (a)
        Gross profit                 379                             283
        Operating expenses         2,105                           2,113
    Restructuring cost
     (net of tax) (b)
        Gross profit                 735
        Operating expenses           799
    One time tax adjustment (c)                                     (246)
                                   4,018           0.13            2,150

    Non-GAAP                      $2,147          $0.07           $5,473
                                  ======          =====           ======

                                           Three months ended
                                    December 31,
                                       2008           March 31, 2008
                                  ------------        --------------
                                  Earnings per       Net         share-
                                share-diluted      income        diluted
                               ---------------   ---------     -----------
    GAAP                           $0.10            $3,733         $0.10
    Non-GAAP adjustments:
    SFAS No. 123(R) adjustment (a)
        Gross profit                                   510
        Operating expenses                           2,557
    Restructuring cost
     (net of tax) (b)
        Gross profit
        Operating expenses
    One time tax adjustment (c)
                                    0.07             3,067          0.09

    Non-GAAP                       $0.17            $6,800         $0.19
                                   =====            ======         =====

    (a) This adjustment reflects the accounting impact of non-cash share-
        based compensation expense pursuant to SFAS123R for the periods
    (b) This is the net of tax impact of the restructuring activities during
        the first quarter of 2009.
    (c) This adjustment reflects the impact on the income tax provision of a
        one-time tax benefit related to research and development tax credits.

SOURCE Omnicell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Omnicell to Release First Quarter 2009 Earnings Results on April 30
2. Omnicell Unveils Tissue Center Solution - Industrys First Integrated Tissue Tracking and Compliance System
3. Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems
4. Omnicell is Awarded Contract by Major National Academic Medical Center
5. Omnicell is Awarded Sole-source Contract by Emory Healthcare
6. Omnicell to Release Fourth Quarter 2008 Earnings Results on January 29
7. Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization
8. Brigham and Womens Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell
9. Omnicell Attains Microsoft Gold Certified Partner Status
10. Omnicell to Present at Piper Jaffray 20th Annual Healthcare Conference
11. Omnicell to Release Second Quarter 2008 Earnings Results on July 21
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
Breaking Medicine Technology: